Chantal Attard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4515616/publications.pdf

Version: 2024-02-01

687363 610901 30 579 13 24 citations h-index g-index papers 30 30 30 844 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Increased Risk for Thromboembolism After Fontan Surgery: Considerations for Thromboprophylaxis. Frontiers in Pediatrics, 2022, 10, 803408.	1.9	4
2	Fibrin clot characteristics and anticoagulant response in a SARSâ€CoVâ€2â€infected endothelial model. EJHaem, 2022, 3, 326-334.	1.0	2
3	Pathophysiological pathway differences in children who present with COVID-19 ARDS compared to COVID -19 induced MIS-C. Nature Communications, 2022, 13, 2391.	12.8	9
4	Neurocognitive Dysfunction and Smaller Brain Volumes in Adolescents and Adults With a Fontan Circulation. Circulation, 2021, 143, 878-891.	1.6	21
5	Impact of adiposity on clinical outcomes in people living with a Fontan circulation. International Journal of Cardiology, 2021, 329, 82-88.	1.7	13
6	Investigating potential protein markers of cardiovascular disease in children with type 1 diabetes mellitus. Proteomics - Clinical Applications, 2021, 15, 2000060.	1.6	2
7	Cross-sectional assessment of haemostatic profile and hepatic dysfunction in Fontan patients. Open Heart, 2021, 8, e001460.	2.3	4
8	Increased platelet activation in SARSâ€CoVâ€2 infected nonâ€hospitalised children and adults, and their household contacts. British Journal of Haematology, 2021, 195, 90-94.	2.5	13
9	Recombinant Factor VIIa in Pediatric Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	1.3	1
10	Long-term outcomes of warfarin versus aspirin after Fontan surgery. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1218-1228.e3.	0.8	16
11	Development and Validation of the Warfarin-Aspirin Bleeding Assessment Tool (WA-BAT) in Children. Journal of Pediatric Hematology/Oncology, 2020, 42, e513-e514.	0.6	1
12	Body Composition in Young Adults Living With a Fontan Circulation: The Myopenic Profile. Journal of the American Heart Association, 2020, 9, e015639.	3.7	48
13	Prevalence and risk factors for low bone density in adults with a Fontan circulation. Congenital Heart Disease, 2019, 14, 987-995.	0.2	11
14	Primary Thromboprophylaxis in Children with Cancer: A Road Less Travelled. Thrombosis and Haemostasis, 2019, 119, 1894-1896.	3.4	2
15	Pathophysiology of thrombosis and anticoagulation post Fontan surgery. Thrombosis Research, 2018, 172, 204-213.	1.7	31
16	Comment on: Generation and optimization of the selfâ€administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. Pediatric Blood and Cancer, 2017, 64, e26725.	1.5	1
17	No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. European Journal of Cardio-thoracic Surgery, 2016, 50, 980-987.	1.4	31
18	Remote Ischemic Preconditioning (RIPC) Modifies the Plasma Proteome in Children Undergoing Repair of Tetralogy of Fallot: A Randomized Controlled Trial. PLoS ONE, 2015, 10, e0122778.	2 . 5	15

#	Article	IF	CITATIONS
19	Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults. Thrombosis Research, 2015, 136, 1303-1309.	1.7	35
20	Differences in the resting platelet proteome and platelet releasate between healthy children and adults. Journal of Proteomics, 2015, 123, 78-88.	2.4	22
21	Platelets from children are hyperâ€responsive to activation by thrombin receptor activator peptide and adenosine diphosphate compared to platelets from adults. British Journal of Haematology, 2015, 168, 526-532.	2.5	26
22	Epidemiology of venous thrombosis in children with cancer. Thrombosis and Haemostasis, 2014, 111, 1015-1021.	3.4	33
23	Plasma Levels of Soluble Interleukin 1 Receptor Accessory Protein Are Reduced in Obesity. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3435-3443.	3.6	15
24	The in-vitro anticoagulant effect of rivaroxaban in neonates. Blood Coagulation and Fibrinolysis, 2014, 25, 237-240.	1.0	28
25	Personalised anticoagulation approach to improve the prevention and treatment of thrombosis. Thrombosis Research, 2014, 134, 204-206.	1.7	O
26	Developmental haemostasis: age-specific differences in the quantity of hemostatic proteins: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2014, 12, 286-286.	3.8	1
27	Developmental hemostasis: ageâ€specific differences in the levels of hemostatic proteins. Journal of Thrombosis and Haemostasis, 2013, 11, 1850-1854.	3.8	156
28	Latent Antithrombin Levels in Children and Adults. Thrombosis Research, 2013, 131, 105-106.	1.7	15
29	First Report of Elevated Monocyte-Platelet Aggregates in Healthy Children. PLoS ONE, 2013, 8, e67416.	2.5	22
30	Letter to the Editor regarding â€~effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma'. Blood Coagulation and Fibrinolysis, 2012, 23, 566.	1.0	1